- Home
- NMI vs GALT Comparison
NMI vs GALT Comparison
Compare NMI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | GALT |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMI | GALT |
|---|---|---|
| Price | $10.02 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 28.4K | ★ 465.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $0.73 |
| 52 Week High | $10.05 | $6.66 |
Technical Indicators
Market Signals| Indicator | NMI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 59.79 |
| Support Level | $9.95 | $5.10 |
| Resistance Level | $10.15 | $6.32 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 82.05 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.